Eli Lilly (LLY) warns against the use of weight-loss drugs, including Zepbound and Mounjaro, for "cosmetic" purposes. The warning comes as Eli Lilly launches a website for telehealth access to obesity drugs.
Shares of autonomous driving developer Mobileye (MBLY) fell more than 25% Thursday after warning of a 50% drop in its first-quarter revenue.
Barclays upgraded Home Depot (HD) to "Overweight," citing 'more positive medium- to long-term narrative around the drivers of home improvement spending and HD's own initiatives to gain share of new and existing customers.'
For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.
Editor's note: This article was written by Luke Carberry Mogan.
Video Transcript
SEANA SMITH: Bit of, I guess, reason to be optimistic here at the start of the trading day. You have the Dow and the S&P now trading above the flat line positive this morning as investors digest the stronger than expected jobs data from ADP. Now, the tech-heavy NASDAQ, though, is still in the red. The move lower coming after Apple got another analyst downgrade.
MADISON MILLS: And taking a look at individual names here. Eli Lilly trending on the Yahoo Finance platform today. The company warning against the use of its popular weight loss drugs, Mounjaro and Zebpound, for cosmetic purposes.
They say they're meant for the treatment of serious diseases and not for cosmetic ones. The company also launching a new website to allow customers to get a weight loss drug prescription through a telehealth provider.
SEANA SMITH: Also trending on Yahoo Finance today is Mobileye. The stock taking a massive hit after warning that it expects a 50% drop in revenue in the first quarter of the year. The self-driving vehicle company blaming this downbeat forecast on excess inventory of its IQ computer chips that are being held by some of its customers. You're looking at a drop of just about 25%.
MADISON MILLS: And Home Depot moving higher after getting an upgrade from Barclays to overweight from equal weight, boosting their price target as well to $372. The Analyst Seth Sigman saying he likes the exposure to housing as home prices may potentially be strengthened by reversing interest rates to come.
